Founded 1990 | ||
 | ||
Stock price HEB (NYSEMKT) US$ 0.55 +0.02 (+3.73%)9 Mar, 9:32 AM GMT-5 - Disclaimer Headquarters Philadelphia, Pennsylvania, United States | ||
Biotech update major breakthrough for hemispherx biopharma inc nyse heb
Hemispherx Biopharma (NYSE MKT: HEB) is a biopharmaceutical company based in Philadelphia, Pennsylvania. Founded in 1990, the company has 32 employees.
Contents
- Biotech update major breakthrough for hemispherx biopharma inc nyse heb
- Biotech company focus hemispherx biopharma inc nyse heb
- References
The company has created an immunomodulatory double stranded RNA drug called Ampligen. The company is developing Ampligen to use as a treatment for chronic fatigue syndrome.
On April 3, 2001, Hemispherx Biopharma, Inc. adjusted and restated its 1999 financial statements to reflect charges relating to an extension of the exercise period to certain warrants as of February 1999.
On April 3, 2006, Hemispherx Biopharma, Inc. restated financial results for 2003 and 2004 due to accounting mistakes related to debentures and warrants issued between March 2003 and August 2005.
Biotech company focus hemispherx biopharma inc nyse heb
References
Hemispherx Biopharma Wikipedia(Text) CC BY-SA